Long-Term Efficacy and Safety of Once-Weekly Semaglutide for Weight Loss in Patients Without Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Semaglutide, a glucagon-like peptide-1 receptor agonist, has demonstrated clinically important weight loss effects in patients with type 2 diabetes. However, its effects on sustained weight loss among individuals without diabetes remains unclear. Our objective was to examine the long-term efficacy and safety of semaglutide use for weight loss among individuals with overweight/obesity and without diabetes. MEDLINE, Embase, and the Cochrane Libraries were systematically searched to identify randomized controlled trials (RCTs) that randomized participants with overweight/obesity but without diabetes to once-weekly 2.4 mg subc...
Source: The American Journal of Cardiology - April 26, 2024 Category: Cardiology Authors: Areesha Moiz, Jeremy Y. Levett, Kristian B. Filion, Katya Peri, Pauline Reynier, Mark J. Eisenberg Source Type: research
Impact of periprocedural myocardial injury on long-term outcomes after percutaneous coronary intervention requiring atherectomy
Percutaneous coronary intervention (PCI) is the most frequent type of coronary revascularization, and is performed with the aim of relieving anginal symptoms, reducing the need for urgent revascularization, and lowering the risk of spontaneous myocardial infarction (1,2). Conversely, patients undergoing PCI are at risk of procedure-related myocardial injury, which may offset these benefits or even worsen the clinical course. Myocardial injury following PCI is assessed by the rise in cardiac biomarkers, commonly cardiac troponin. (Source: The American Journal of Cardiology)
Source: The American Journal of Cardiology - April 25, 2024 Category: Cardiology Authors: Hiroki Emori, Yasutsugu Shiono, Nehiro Kuriyama, Yasuhiro Honda, Kosuke Kadooka, Takeaki Kudo, Kenji Ogata, Toshiyuki Kimura, Kensaku Nishihira, Atsushi Tanaka, Yoshisato Shibata Source Type: research
Real-World Experience and Outcomes with Percutaneous Coronary Intervention for Protected versus Unprotected Left Main Coronary Artery Disease: Insights from the VA CART Program
Practice patterns and outcomes of protected left main (PLM) and unprotected left main (ULM) percutaneous coronary intervention (PCI) are not well defined in contemporary US clinical practice. Data collected from all Veteran Affairs (VA) catheterization laboratories participating in the Clinical Assessment Reporting and Tracking Program between 2009 and 2019. The analysis included 4,351 patients undergoing left main PCI, of which 1,306 pairs of PLM and ULM PCI were included in a propensity matched cohort. (Source: The American Journal of Cardiology)
Source: The American Journal of Cardiology - April 25, 2024 Category: Cardiology Authors: Pedro Engel Gonzalez, Annika Hebbe, Yasin Hussain, Rohan Khera, Subhash Banerjee, Mary E Plomondon, Stephen W. Waldo, Steven E. Pfau, Jeptha P. Curtis, Samit M. Shah Source Type: research
Robotic Assisted Hybrid Coronary Revascularization
The authors reported 285 patients that underwent reverse robotic assisted Hybrid Coronary Revascularization (HCR). Reverse HCR consists in PCI in non left anterior descending (LAD) coronary artery vessels performed within 30 days prior to robotic assisted left internal thoracic artery (LTA) harvesting and LTA to LAD manual anastomosis through a 4 cm left minithoracotomy. (Source: The American Journal of Cardiology)
Source: The American Journal of Cardiology - April 24, 2024 Category: Cardiology Authors: Andrea Ballotta Source Type: research
The iATTEND Trial: A Trial Comparing Hybrid versus Standard Cardiac Rehabilitation
The improving ATTENDance (iATTEND) to cardiac rehabilitation (CR) trial tested the hypotheses that hybrid cardiac rehabilitation (HYCR = combination of virtual and in-facility CR sessions) would result in greater attendance compared to traditional, facility-based only CR (FBCR) and yield equivalent improvements in exercise capacity and health status. Patients were randomized to HYCR (n=142) or FBCR (n=140), stratified by sex a nd race. Attendance was assessed as number of CR sessions completed within 6 mo (primary end-point) and % patients completing 36 CR sessions. (Source: The American Journal of Cardiology)
Source: The American Journal of Cardiology - April 24, 2024 Category: Cardiology Authors: Steven J. Keteyian, Crystal Grimshaw, Jonathan K. Ehrman, Dennis J. Kerrigan, Khaled Abdul-Nour, David E. Lanfear, Clinton A. Brawner Source Type: research
Maternal and Fetal Outcomes in Pulmonary Hypertension During Pregnancy: A Contemporary Nationwide Analysis
Pulmonary hypertension (PH) disproportionately affects women, presenting challenges during pregnancy. Historically, patients with PH are advised to avoid pregnancy; however, recent reports have indicated that the incidence of adverse events in pregnant females with PH may be lower than previously reported. (Source: The American Journal of Cardiology)
Source: The American Journal of Cardiology - April 23, 2024 Category: Cardiology Authors: Anand Maligireddy, Ahmad Jabri, Mohammad Zghouzi, Chaitanya Rojulpote, Gabriella VanAken, Chaitra Janga, Ryhm Radjef, Herbert Aronow, Rana Awdish, Bryan Kelly, Gillian Grafton, Timir K Paul, Chien-Jung Lin, Deana Mikhalkova, Khaldoon Alaswad, Domingo Fran Source Type: research
Surveillance Imaging and Management of Cardiac Sarcoidosis after Advanced Heart Failure Therapies
Cardiac sarcoidosis (CS), an inflammatory disorder characterized by granulomatous inflammation, can manifest as heart failure (HF), ventricular arrhythmias, and conduction disease (1). Despite immunosuppression and medical therapy for HF, a subset of CS patients will progress to end-stage HF requiring left ventricular assist device (LVAD) therapy and/or heart transplantation (HT) which are associated with excellent outcomes (2, 3). The optimal surveillance strategy for monitoring CS recrudescence after advanced heart failure therapies remains undefined. (Source: The American Journal of Cardiology)
Source: The American Journal of Cardiology - April 23, 2024 Category: Cardiology Authors: Richa Gupta, Francisca Bermudez, Tania Vora, Navid Homayouni, Gaby Weissman, Ajay Kadakkal, Nana Afari-Armah, Sriram Rao, Phillip H. Lam, Maria E. Rodrigo, Mark Hofmeyer, Mrinalini Krishnan, Keki Balsara, Samer S. Najjar, Farooq H. Sheikh Tags: Brief report Source Type: research
Corrigendum to ‘Impact of Cardiac Implantable Electronic Devices on Cost and Length of Stay in Patients With Surgical Aortic Valve Replacement and Transcutaneous Aortic Valve Implantation’ [The American Journal of Cardiology 192 (2023) 69-78]
That authors regret that due to a clerical mistake oversight, funding was incorrectly acknowledged, specifically funding by the American Heart Association (award number 17POST33400211). The authors would like to apologise for any inconvenience caused. (Source: The American Journal of Cardiology)
Source: The American Journal of Cardiology - April 22, 2024 Category: Cardiology Authors: Hiroyuki Sawatari, Anwar A. Chahal, Raheel Ahmed, George B. Collins, Saurabh Deshpande, Mohammed Y. Khanji, Rui Provedenciae, Hassan Khan, Syed Emir Irfan Wafa, Mohammad N. Salloum, Shahid Karim, Jayaprakash Shenthar, Yong-Mei Cha, Matthew Hyman, Peter A. Tags: Corrigendum Source Type: research
Editorial to “Association of Left Atrial Appendage Morphology and Function with Stroke and Transient Ischemic Attack in Atrial Fibrillation Patients”
Atrial fibrillation (AF) is the most commonly encountered arrhythmia in clinical practice and is an independent risk factor for strokes. A thromboembolic event risk assessment based on the CHA2DS2-VASc score is recommended by the guidelines. However, strokes also occur even in some populations with low CHA2DS2-VASc scores. Thus, new factors to improve the risk stratification of thromboembolic events are needed. A major embolic source associated with AF is the left atrial appendage (LAA). Previous reports showed that the LAA endocardium has more enhanced expression of a prothrombotic profile and proinflammatory proteins tha...
Source: The American Journal of Cardiology - April 22, 2024 Category: Cardiology Authors: Satoshi Higa Tags: Editorial Source Type: research
Off-label Use of Balloon-Expandable Transcatheter Valves to Treat Pure Aortic Regurgitation
Transcatheter aortic valve implantation (TAVI) in native pure aortic regurgitation (AR) with off-label use of balloon expandable valves (BEV) has been reported. However, there are scant data regarding optimal oversizing and its safety and our study assessed BEV oversizing and outcomes of TAVI. Thirteen consecutive tricuspid aortic valve patients undergoing transfemoral TAVIs for pure AR with Sapien BEV at our centre between 2019 and 2023 (69.2% males, mean age 80.8 years, STS 4.0%) were divided into small annulus group ( ≤618mm2, SA) where ≥20% oversizing is achievable based on published data on BEV overexpansion, and ...
Source: The American Journal of Cardiology - April 22, 2024 Category: Cardiology Authors: Mateusz Orzalkiewicz, Marco Foroni, Francesco Chietera, Francesco Bendandi, Alessandro Mazzapicchi, Antonio Giulio Bruno, Gabriele Ghetti, Nevio Taglieri, Cinzia Marrozzini, Nazzareno Gali è, Tullio Palmerini, Francesco Saia Tags: Brief report Source Type: research
Disentangling Knots of Misfolded Proteins: Do We Really Know the Prognostic Implications of the Pathogenic V122I TTR Variant?
The valine to isoleucine replacement at position 122 (V122I) of the transthyretin (TTR) protein destabilizes its tertiary structure and is the rate-limiting step towards TTR amyloidogenesis. This variant is virtually exclusive to those of African ancestry with a carrier frequency of ∼3-4% (1) and is the most common cause of hereditary transthyretin cardiac amyloidosis (ATTR-CA) in the world (1, 2). However, because the vast majority of individuals with V122I TTR variant ATTR cardiac amyloidosis (V122I ATTRv) are Black, a population with disparately worse heart failure outcome s than white individuals, more clarity is nee...
Source: The American Journal of Cardiology - April 22, 2024 Category: Cardiology Authors: Anas Jawaid, Isabel Wees, Justin L. Grodin Tags: Editorial Source Type: research
Timing of Revascularization in Patients with Acute Coronary Syndrome: Why Is Earlier Better?
Multivessel coronary artery disease is present in up to half of patients presenting with acute coronary syndrome (1). While the debate regarding the treatment of multivessel disease in the setting of ST-elevation myocardial infarction (STEMI) has largely been settled, compelling evidence to guide the timing of complete revascularization in the setting of non-ST-elevation myocardial infarction (NSTEMI) has been lacking. Two recent trials directly address this topic (2,3) and prompted Cheema and colleagues to complete a systemic review and meta-analysis (4). (Source: The American Journal of Cardiology)
Source: The American Journal of Cardiology - April 22, 2024 Category: Cardiology Authors: David J. Schneider Tags: Editorial Source Type: research
Management of Systemic Inflammatory Response Syndrome after Cardiovascular Interventions. Diagnostic, Prognostic and Therapeutic Implications
Scientific and clinical observations report more frequent systemic inflammatory response syndrome (SIRS) cases following cardiovascular interventions (1). Current diagnosis of SIRS is based on the presence of at least two of the following four criteria: temperature38.0 °C, heart rate ≥90 beats/min, respiratory rate>20 breaths/min, or partial pressure of carbon dioxide (PaCO2)12 or (Source: The American Journal of Cardiology)
Source: The American Journal of Cardiology - April 20, 2024 Category: Cardiology Authors: Carlo Mannina, Annapoorna Kini, Andreina Carbone, Eric Neibart, Eduardo Bossone, Francesca Romana Prandi, Rami Tadros, Giovanni Esposito, Raimund Erbel, Samin K Sharma, Stamatios Lerakis Source Type: research
Longer Duration DAPT in Medically Treated MI: What is the Strength of the Evidence?
A few studies have demonstrated the benefit of dual antiplatelet therapy (DAPT) during the first 3-12 months after AMI in medically managed patients (1-3). However, the benefit of more prolonged DAPT is poorly defined. The guidelines from national societies on the use of antiplatelet therapy after acute coronary syndromes (ACS) with or without percutaneous coronary intervention (PCI)/stenting continue to evolve, with more recent guidelines recommending a reduced duration and intensity of therapy in certain situations (4, 5). (Source: The American Journal of Cardiology)
Source: The American Journal of Cardiology - April 20, 2024 Category: Cardiology Authors: Jeffrey L Anderson Tags: Editorial Source Type: research
Partial CArdiac Denervation to prevent PostOperative Atrial Fibrillation after coronary artery bypass grafting (pCAD-POAF): study protocol for a randomized controlled trial
This study is aimed to evaluate the effect of partial cardiac denervation, which is achieved by cutting off the ligament of Marshall and resecting the fat pad along the Waterston groove, on the prevention of POAF after CABG. Patients planned for CABG at our center will be screened for eligibility for this study. (Source: The American Journal of Cardiology)
Source: The American Journal of Cardiology - April 20, 2024 Category: Cardiology Authors: Ziang Yang, Xieraili Tiemuerniyazi, Shengkang Huang, Yangwu Song, Fei Xu, Wei Feng Source Type: research
